JP2024521902A5 - - Google Patents
Info
- Publication number
- JP2024521902A5 JP2024521902A5 JP2023574388A JP2023574388A JP2024521902A5 JP 2024521902 A5 JP2024521902 A5 JP 2024521902A5 JP 2023574388 A JP2023574388 A JP 2023574388A JP 2023574388 A JP2023574388 A JP 2023574388A JP 2024521902 A5 JP2024521902 A5 JP 2024521902A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- group
- leukemia
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/098067 | 2021-06-03 | ||
| CN2021098067 | 2021-06-03 | ||
| PCT/CN2022/096734 WO2022253289A1 (en) | 2021-06-03 | 2022-06-02 | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521902A JP2024521902A (ja) | 2024-06-04 |
| JP2024521902A5 true JP2024521902A5 (https=) | 2025-06-02 |
Family
ID=77021000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574388A Pending JP2024521902A (ja) | 2021-06-03 | 2022-06-02 | スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250333421A1 (https=) |
| EP (1) | EP4347600A1 (https=) |
| JP (1) | JP2024521902A (https=) |
| CN (1) | CN117425659A (https=) |
| BR (1) | BR112023025436A2 (https=) |
| CA (1) | CA3218340A1 (https=) |
| WO (1) | WO2022253289A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102984941B (zh) | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
-
2022
- 2022-06-02 JP JP2023574388A patent/JP2024521902A/ja active Pending
- 2022-06-02 CN CN202280039198.7A patent/CN117425659A/zh active Pending
- 2022-06-02 EP EP22729426.1A patent/EP4347600A1/en active Pending
- 2022-06-02 WO PCT/CN2022/096734 patent/WO2022253289A1/en not_active Ceased
- 2022-06-02 US US18/566,249 patent/US20250333421A1/en active Pending
- 2022-06-02 CA CA3218340A patent/CA3218340A1/en active Pending
- 2022-06-02 BR BR112023025436A patent/BR112023025436A2/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3464248B1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| CN116531380B (zh) | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 | |
| TWI487702B (zh) | Ｃ型肝炎病毒抑制劑 | |
| AU2003260002B2 (en) | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | |
| CN106573897B (zh) | 作为mIDH1抑制剂的苯并咪唑-2-胺 | |
| KR101345920B1 (ko) | 키나제 억제제로서의 피콜린아미드 유도체 | |
| IL322109A (en) | Tricyclic compounds for cancer treatment | |
| JP2018048121A (ja) | キナーゼ阻害剤としての新規環置換ｎ−ピリジニルアミド | |
| JP2015509983A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| JP2011518193A5 (https=) | ||
| JP2024518497A5 (https=) | ||
| KR20050083610A (ko) | 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법 | |
| JP2004535447A5 (https=) | ||
| EP3456355A1 (en) | Compositions comprising a pi3k inhibitor and an hdac inhibitor | |
| JP2011518190A5 (https=) | ||
| JP2021534108A5 (https=) | ||
| JP2021519785A5 (https=) | ||
| JP2024518434A5 (https=) | ||
| JP2024518425A5 (https=) | ||
| JP2024521902A5 (https=) | ||
| US20100022596A1 (en) | Epothilone analogues | |
| JP2024519322A5 (https=) | ||
| US8946409B2 (en) | Polycyclic β lactam derivatives for the treatment of cancer | |
| JP2024525145A5 (https=) |